AFFILIATIONS
1 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
2 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
3 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
4 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
5 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
6 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
7 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
8 H. Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, Tampa, Florida, United States, The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States
9 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
ABSTRACT
Background:
Fludarabine-cyclophosphamide (FluCy) is the standard lymphodepletion regimen before chimeric antigen receptor (CAR) T-cell therapy; however, fludarabine shortages and concerns regarding toxicity have increased interest in bendamustine as an alternative. Comparative data on long-term survival, immune-mediated toxicities, infections, and hematologic recovery remain limited. We compared clinical outcomes after bendamustine- versus FluCy-based lymphodepletion after CD19 CAR T-cell therapy for relapsed/refractory large B-cell lymphoma (LBCL).
Methods:
In this retrospective study, we analyzed patients with LBCL who received commercial CD19 CAR T-cell therapy (axicabtagene ciloleucel or tisagenlecleucel) from December 2017 through June 2022 after bendamustine- or FluCy-based lymphodepletion using the Center for International Blood and Marrow Transplant Research (CIBMTR) registry (study P-6093). The primary endpoint was overall survival (OS). Secondary endpoints included cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), day-100 infections, infection-related mortality, and neutrophil recovery. OS was estimated by Kaplan-Meier methods. Multivariable Cox models adjusted for age, HCT-CI, bridging therapy, and CAR T-cell product. Multivariable logistic models evaluated secondary outcomes. Propensity-based sensitivity analyses assessed robustness of survival findings. Statistical significance was defined as P<0.05.
Results:
Among 3,287 patients, 103 received bendamustine and 3,184 received FluCy. Patients in the bendamustine group were more often aged ≥65 years (52.4% vs 40.5%; P=0.020), more frequently received bridging therapy (35.0% vs 24.2%; P=0.019), had higher rates of complete or partial remission at infusion, and predominantly received tisagenlecleucel (89.3% vs 13.6%; P<0.001). Median follow-up was 25.4 months with bendamustine and 23.6 months with FluCy. OS did not differ significantly between groups. Twelve-month OS was 63.3% versus 63.7% and 24-month OS was 48.9% versus 49.3% for bendamustine and FluCy, respectively. Median OS was 21.6 versus 23.5 months (log-rank P=0.87). After multivariable adjustment, FluCy was not associated with OS compared with bendamustine (aHR 1.07, 95% CI 0.78–1.48; P=0.665), with consistent findings in propensity-based sensitivity analyses. FluCy was associated with higher odds of any-grade CRS (aOR 2.33, 95% CI 1.32–4.12; P=0.004), any-grade ICANS (aOR 3.02, 95% CI 1.16–7.87; P=0.023), and viral infection (aOR 3.56, 95% CI 1.14–11.11; P=0.028). Grade ≥2 CRS and ICANS, bacterial and fungal infections, and infection-related mortality did not differ significantly. Bendamustine was associated with delayed neutrophil recovery (HR 0.27, 95% CI 0.22–0.34; P<0.001). Tocilizumab use (aOR 2.03, P=0.048) and intravenous immunoglobulin replacement (aOR 8.11, P=0.004) were more common after FluCy.
Conclusions:
In this retrospective registry cohort, overall survival did not differ significantly between bendamustine- and FluCy-based lymphodepletion after CD19 CAR T-cell therapy for LBCL. FluCy was associated with higher odds of any-grade CRS, ICANS, and viral infection, whereas bendamustine was associated with delayed neutrophil recovery. Bendamustine may represent a reasonable alternative when fludarabine exposure is undesirable, although prospective validation and careful hematologic monitoring are warranted.
DISCLOSURES
Muhammad Kashif Amin, MD, MSc, FACP: No relevant conflicts of interest to declare.